Elsevier

The American Journal of Cardiology

Volume 184, 1 December 2022, Pages 41-47
The American Journal of Cardiology

Comparison of Outcomes in Patients With Atrial Fibrillation Under Oral Anticoagulation Therapy Analyzed by Body Weight (<60, 60 to 100, and >100 kg)

https://doi.org/10.1016/j.amjcard.2022.07.028Get rights and content

There is limited knowledge regarding the efficacy and safety of fixed-dose oral anticoagulants in overweight patients because of the possible increased risk of embolism and hemorrhage. This study aimed to evaluate embolic, hemorrhagic, and mortality events in anticoagulated patients, administered both antivitamin K and direct oral anticoagulants based on the body weight (<60 kg, 60 to 100 kg and >100 kg). A retrospective registry-based cohort study including all consecutive patients with a diagnosis of atrial fibrillation between January 2014 and January 2018 in the health area of Vigo (Galicia, Spain) was used (CardioCHUVI‐AF registry; ClinicalTrials.gov identifier: NCT04364516). The final cohort comprised 11,821 AF patients. The cohort was classified into 3 categories: low body weight ([LBW], <60 kg, 924 patients); middle body weight (60 to 100 kg, 9,546 patients); and high body weight ([HBW], >100 kg, 958 patients). Outcomes were predicted using the Fine and Gray model and Cox proportional hazards model when appropriate. Middle body weight was the reference group. No association was found between the weight and major bleeding in the univariate analyses: LBW with a sub-distribution hazard ratio (sHR) of 1.13 (95% confidence interval [CI] 0.92 to 1.41), and HBW with an sHR of 1.02 (95% CI 0.83 to 1.26). Stroke/systemic embolism events occurred in 817 patients (6.6%). In the univariate analyses, we found an association between weight and risk of stroke/systemic embolism: LBW sHR 1.37 (95% CI 1.09 to 1.72), and HBW sHR 0.66 (95% CI 0.49 to 0.89) but no association was found in the multivariable model. The same situation was observed with all-cause death: in the univariable model, LBW presented a hazard ratio of 1.48 (95% CI 1.31 to 1.68) and the HBW group presented a hazard ratio of 0.53 (95%CI 0.44 to 0.63) whereas no significant association was found in the multivariable model. We conclude that in our registry, extreme weights were not related to more events during follow-up.

Section snippets

Methods

A retrospective registry-based cohort study including all consecutive patients (n = 16,202) with a diagnosis of atrial fibrillation (AF) between January 2014 and January 2018 in the health area of Vigo (Galicia, Spain) was used (CardioCHUVI‐AF registry; ClinicalTrials.gov identifier: NCT04364516). Patients were identified through administrative databases and regional electronic medical records systems at both the hospital and outpatient levels. Clinical, laboratory, and therapeutic data were

Results

A total of 11,821 patients with AF under anticoagulation were included for statistical analysis, 924 with LBW, 9,393 with MBW, and 958 with HBW. Baseline characteristics of the total cohort according to the group of body weight are summarized in Table 1. The mean age was 77.2±8.9 years and approximately 52% of the participants were female. Most of the patients were treated with VKA (85%) and a few with DOACs (14%).

Regarding the characteristics of weight groups, patients with HBW had a higher

Discussion

We evaluated a large registry of more than 11,000 patients with AF under anticoagulant treatment with VKAs and with DOACs. After analyzing the events according to the weight group, the main findings are: (1) In the univariate analysis, the LBW group compared with the MBW group presented a higher risk of embolic events, mortality, and combined event. In contrast, HBW patients presented less risk. (2) In the multivariable analysis, no significant differences were found depending on the weight

Disclosures

The authors have no conflicts of interest to declare.

References (24)

  • R De Caterina et al.

    The non-vitamin K antagonist oral anticoagulants (NOACs) and extremes of body weight-a systematic literature review

    Clin Res Cardiol

    (2017)
  • J Steffel et al.

    The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation

    Eur Heart J

    (2018)
  • Cited by (0)

    Daiichi Sankyo (Madrid, Spain), Bayer (Barcelona, Spain), Boehringer Ingelheim (Barcelona, Spain), and Pfizer (Madrid, Spain), have provided unconditional financial support for this study.

    View full text